Similarly, FoundationOne® CDx (Foundation Medicine Inc., Cambridge, MA, USA) and OncomineTM Dx Target Test (Thermo Fisher Scientific Inc., Waltham, MA, USA) were adapted for EGFR screening for patients with advanced or metastatic NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.